The FDA is awarding national priority vouchers to Compass Pathways and the Usona Institute as the Trump administration looks ...

Compass Pathways stock rallies as Trump’s new executive order aims at accelerating approval and research of psychedelic ...

Compass Pathways (NASDAQ:CMPS) is a biotech company focused on developing psychedelic treatments for mental health issues.

Why COMPASS Pathways is Back on Investors’ Radar Interest in COMPASS Pathways (NasdaqGS:CMPS) has picked up after a White House executive order aimed at accelerating medical treatments for serious ...

Compass Pathways stock surged Monday after President Donald Trump signed an executive order tied to psychedelic drugs.

Compass Pathways may be the first to benefit from an accelerated approval process.

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today an invitation for U.S. based ...

COMPASS Pathways (CMPS) stock jumped 25% after Trump's executive order on psychedelic research. Positive Phase 3 data boosts ...

View COMPASS Pathways Plc Sponsored ADR CMPS stock quote prices, financial information, real-time forecasts, and company news from CNN.

LONDON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it has entered into a collaboration with Osmind, the ...